About this visual
Maintenance strategies, oral therapies, and body-composition findings from ECO.
Sources & further reading
Original LinkedIn post and discussion ↗
Link shared in the original post: Lilly: ECO presentation materials ↗
Link shared in the original post: Lilly: maintenance trial results, May 12, 2026 ↗
Link shared in the original post: Novo Nordisk: ECO update (916545) ↗
Link shared in the original post: Novo Nordisk: ECO update (916548) ↗
Additional references appear in the infographic and the original LinkedIn discussion.




Several major obesity medicine updates were presented at the European Congress on Obesity:
1. SURMOUNT-MAINTAIN
This Eli Lilly study looked at patients who first lost weight on Zepbound, then were randomized to either stay on their full dose, reduce to 5 mg, or switch to placebo for one year.
The results:
- Patients who stayed on their maximum tolerated dose maintained essentially all of their weight loss.
- Patients who reduced to Zepbound 5 mg still maintained most of their weight loss, but regained about 12 pounds on average.
- Patients who switched to placebo regained much more, and about 67% eventually needed rescue therapy.
Takeaway: staying on treatment matters. A lower maintenance dose may work for some patients, but stopping treatment led to significantly more regain.
2. ATTAIN-MAINTAIN
This Eli Lilly study looked at patients who had previously lost weight on either Wegovy or Zepbound, then switched to either oral Foundayo or placebo for one year.
The results:
- Patients who switched from Wegovy to oral Foundayo regained only about 2 pounds on average.
- Patients who switched from Zepbound to oral Foundayo regained about 11 pounds on average.
- Patients who switched to placebo regained significantly more.
Takeaway: oral maintenance therapy could become a very useful option, especially for patients who want to move away from injections. But switching from Zepbound to a GLP-1 only option may come with some regain.
3. High-dose Wegovy 7.2 mg
In Novo Nordisk's STEP UP, early responders to semaglutide 7.2 mg, meaning those who lost at least 15% by week 24, went on to lose an average of 27.7% by week 72.
That is a very impressive response for a GLP-1 based medication.
4. Wegovy pill
In Novo Nordisk's OASIS 4, early responders to oral semaglutide 25 mg lost 21.6% by week 64.
The pill is not just about convenience. It may become a very meaningful treatment option.
5. Body composition data
Novo also presented data showing about 84% of the weight loss with semaglutide 2.4 mg and 7.2 mg came from fat mass, with significant reductions in visceral fat.
There was some lean mass loss, which we expect with large weight loss, but muscle function was reportedly preserved.
My takeaway:
This is a big week for obesity medicine.
We are seeing more evidence that obesity treatment needs to be long-term, individualized, and focused on more than just the number on the scale.
Higher doses, oral options, step-down strategies, and maintenance therapy are all going to be part of the conversation moving forward.
The field is moving fast and patients are going to have more options than ever!